HB1801
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.HB1801 is one of 88 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
4
Indications
10
Total Trials
9
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Tianeptine
PfizerPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2027
Phase 2Not yet recruiting
Breast Cancer
NCT07116824
Phase 1/2Not yet recruiting
Locally Advanced or Metastatic Solid Tumors
NCT06682611
Phase 2/3Not yet recruiting
Non-Small Cell Lung Cancer
NCT06319313
Phase 3Active, not recruiting
HER2-Positive Breast Cancer
NCT06747338
Phase 3Recruiting
Breast Cancer
NCT05838066
Clinical
Trials by Indication[1]
Breast Cancer5 trials
Non-Small Cell Lung Cancer2 trials
Locally Advanced or Metastatic Solid Tumors1 trial
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled
HER2-negative Breast Cancer1 trial
HER2-positive Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB1801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details